Publications and Presentations

Publications 

  • Myeloma in the Real World: What Is Really Happening? Bergin K, McQuilten Z, Moore E, Wood E, Spencer A. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):133-144.
  • Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. Bergin K, Moore E, McQuilten Z, Wood E, Augustson B, Blacklock H, Ho J, Horvath N, King T, McNeil J, Mollee P, Quach H, Reid CM, Rosengarten B, Walker P, Spencer A. BMC Med Res Methodol. 2016 Nov 9;16(1):151.

Presentations

2017

  • A. Spencer et al., MRDR Interest Group meeting, HAA, Sydney, November 2017
  • J. Ho, Renal impairment in myeloma: patient & disease characteristics, treatment, stem cell transplant & outcomes from the ANZ MRDR,  HAA, Sydney, November 2017 
  • H. Blacklock, Polynesian ethnicity and outcomes for multiple myeloma in New Zealand: a single centre study from the ANZ MRDR (poster), HAA, Sydney, November 2017
  • E. Moore et al., Patient reported outcome measures in multiple myeloma: real-time reporting to improve care (methodology of the My-PROMPT study) (poster), HAA, Sydney, November 2017
  • J. Ho, Renal impairment in myeloma: patient characteristics, treatment modalities, stem cell transplant & outcomes from the ANZ MRDR (poster), European Haematology Association Congress, June 2017 
  • A. Spencer, The myeloma and related diseases registry: a tool for practice improvement, Victorian Integrated Cancer Services Conference, Melbourne, May 2017
  • A. Kalff, Myeloma Australia, Medical scientific advisory group (MSAG) meeting, Melbourne, May 2017
  • K. Bergin et al., Rates of Upfront Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma (poster), International Myeloma Workshop, New Delhi, February 2017
  • E. Moore et al., Maturing data from the ANZ Myeloma and Related Diseases Registry (poster), International Myeloma Workshop, New Delhi, February 2017

Talks including reference to or introduction of the MRDR:

  • H. Blacklock/T. King, National Haematology Nurses meeting, September 2017

2016

  • E. Wood, Australian Centre for Blood Diseases and Monash Health Research Symposium, Melbourne, November 2016 
  • A. Spencer et al., MRDR Interest Group meeting, HAA, Melbourne, November 2016
  • Z. McQuilten, Putting the pieces together – Epidemiology Practice and Outcomes in Australia and New Zealand, National Myeloma Workshop, Yarra Valley, Vic, September 2016
  • K. Bergin et al. Rates of Upfront Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (poster), National Myeloma Workshop, Yarra Valley, Vic September 2016
  • E. Moore et al. Renal impairment in myeloma: Characteristics and outcomes in patients with and without renal impairment in the ANZ Myeloma and Related Diseases Registry (poster), National Myeloma Workshop, Yarra Valley, Vic September 2016
  • E. Moore, MRDR: Maturing data, HSANZ Nurses Group, Myeloma Special Practice Network Education Seminar, August 2016
  • E. Moore, MRDR: sustaining growth, Monash SPHPM Registry SIG, June 2016
  • A. Spencer, MRDR presentation to ALLG, ALLG Scientific Meeting, May 2016
  • B. Rosengarten, Myeloma Awareness Day Meeting, Sydney, May 2016

Talks including reference to or introduction of the MRDR:

  • S. Gibbs, Myeloma lectures, Royal Darwin Hospital, Aug 2016

2015

  • E. Wood, Australian Centre for Blood Diseases and Monash Health Research Symposium, Melbourne, November 2015
  • A. Spencer, Korean Society of Hematology annual meeting, Seoul, November 2015
  • E. Moore et al., HAA, Adelaide October 2015 (poster)
  • A. Spencer, MRDR Interest Group meeting, HAA, Adelaide, October 2015
  • E. Moore et al., International Myeloma Workshop, Rome, September 2015 (poster)

Talks including reference to or introduction of the MRDR:

  • A. Kalff, Binding site Educational Workshop, Melbourne, November, 2015
  • A. Kalff, Myeloma Australia, Medical scientific advisory group (MSAG) meeting, Melbourne, November, 2015
  • T. King, Update from IMW 2015 Rome: Nursing Symposium. HSANZ NG NSW Dinner Meeting. Sydney, November 2015 (poster)
  • T. King, Best practice in the administration of chemotherapy: Bortezomib focus. Tata Memorial Hspt Mumbai; Cancer Institute Chennai; Apollo Hospital Chennai; All India Institute of Medical Sciences (AIMS) Delhi; Rajiv Gandhi Cancer Institute Delhi India, August, 2015
  • A. Kalff, Myeloma Australia, medical scientific advisory group (MSAG) meeting, Melbourne, May, 2015

2014

  • A. Spencer, Myeloma Scientific Advisory Group, Myeloma Foundation Australia, Melbourne, Victoria
  • A. Spencer, MRDR Interest Group Meeting, HAA, Perth, Western Australia, October 2014

Talks including reference to or introduction of the MRDR:

  • T. King, The Clinical Care of Multiple Myeloma Patients with Targeted Therapy. Taipei, Taiwan, November 2014
  • T. King, The Clinical Care of Multiple Myeloma Patients with Targeted Therapy. Kaohsiung, Taiwan, November 2014
  • T. King, Making sense of myeloma: An overview of treatment. Leukaemia and Blood Cancer Foundation & HSANZ Nurses Group Educational meeting for nurses, September 2014 
  • T. King, Myeloma: An overview of disease, treatments and management of side effects. Leukaemia and Blood Cancer Foundation Patient and Family Forum Auckland New Zealand, September 2014
  • T. King, The Clinical Care of Multiple Myeloma Patients. The First Affiliated Hospital of College of Medicine Zhejiiang University. Hangzhou, China, February 2014
  • T. King, The Clinical Care of Multiple Myeloma Patients. Shanghai Changzheng, Shanghaim, China, February 2014
  • T. King, The Clinical Care of Multiple Myeloma Patients. Institute of Haematology and Blood Diseases Hospital Chinese Academy of Medical Sciences. Tianjin, China, February 2014

2013

  • A. Spencer HAA Investigator Meeting, Gold Coast, Queensland